Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus documentMarieke Biegstraaten, Carla E. M. Hollak, Reynir Arngrı́msson et al.|Orphanet Journal of Rare Diseases|2015Cited by 345
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry RegistryAlberto Ortíz, David G. Warnock, Ademola K. Abiose et al.|Journal of Medical Genetics|2016Cited by 147
Use of a rare disease registry for establishing phenotypic classification of previously unassigned <i>GLA</i> variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroupDominique P. Germain, David G. Warnock, João Paulo Oliveira et al.|Journal of Medical Genetics|2020Cited by 66
Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosisLinda van der Tol, Gabor E. Linthorst, Robin Lachmann et al.|Molecular Genetics and Metabolism|2014Cited by 64